Wolfe Research analyst Andy Chen initiates coverage on Akero Therapeutics (NASDAQ: AKRO) with a Outperform rating.The analyst comments "Outperform, PT ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE